MRNS Marinus Pharmaceuticals Inc.

1.17
+0.06  (+5%)
Previous Close 1.11
Open 1.12
Price To Book 1.31
Market Cap 61,517,235
Shares 52,578,833
Volume 633,774
Short Ratio
Av. Daily Volume 1,027,135

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data due by the end of 3Q 2019.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 negative data released July 23, 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 3 top-line data due 3Q 2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Phase 3 top-line data due 2021.
Ganaxolone (Violet Study)
PCDH19-related epilepsy

Latest News

  1. Main Line pharmaceutical firm finds new CEO in-house
  2. Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
  3. Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today
  4. Marinus Sinks To 2-Year Low As Postpartum Depression Drug Found Ineffective At 28 Days
  5. Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
  6. Is Marinus Pharmaceuticals Inc (MRNS) A Good Stock To Buy?
  7. 5 stocks trading at under $10 worth discovering
  8. Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years
  9. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
  10. Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences
  11. Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
  12. Marinus Pharmaceuticals: 1Q Earnings Snapshot
  13. Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
  14. How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?
  15. Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
  16. Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
  17. Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
  18. Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
  19. Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
  20. Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why